These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 31645880)

  • 21. Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
    Pinilla-Ibarz J; Sweet KL; Corrales-Yepez GM; Komrokji RS
    Onco Targets Ther; 2016; 9():4937-57. PubMed ID: 27570458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myelofibrosis: clinicopathologic features, prognosis, and management.
    O'Sullivan JM; Harrison CN
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):121-131. PubMed ID: 29741513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peritoneal carcinomatosis-like implants of extramedullary hematopoiesis. An insolite occurrence during splenectomy for myelofibrosis.
    Casaccia M; Fornaro R; Frascio M; Palombo D; Stabilini C; Firpo E; Gianetta E
    Int J Surg Case Rep; 2017; 41():9-11. PubMed ID: 29024842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].
    Liu JX; Chen W; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Feb; 26(1):283-286. PubMed ID: 29397859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera.
    Alchalby H; Kröger N
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S36-41. PubMed ID: 25486953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging treatment options for myelofibrosis: focus on pacritinib.
    Chow V; Weissman A; O'Connell CL; Mehrvar A; Akhtari M
    Onco Targets Ther; 2016; 9():2655-65. PubMed ID: 27226728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
    McMullin MF; Harrison CN; Niederwieser D; Demuynck H; Jäkel N; Gopalakrishna P; McQuitty M; Stalbovskaya V; Recher C; Theunissen K; Gisslinger H; Kiladjian JJ; Al-Ali HK
    Exp Hematol Oncol; 2015; 4():26. PubMed ID: 26380150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
    Mesa RA; Tefferi A
    Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic hematopoietic stem-cell transplantation for myelofibrosis.
    Zhang L; Yang F; Feng S
    Ther Adv Hematol; 2020; 11():2040620720906002. PubMed ID: 32110286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How I treat splenomegaly in myelofibrosis.
    Cervantes F
    Blood Cancer J; 2011 Oct; 1(10):e37. PubMed ID: 22829071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Momelotinib for the treatment of myelofibrosis.
    Bose P
    Blood; 2024 Jul; ():. PubMed ID: 38958484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date.
    Bassiony S; Harrison CN; McLornan DP
    Ther Clin Risk Manag; 2020; 16():889-901. PubMed ID: 33061394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and future therapies for myelofibrosis.
    Asher S; McLornan DP; Harrison CN
    Blood Rev; 2020 Jul; 42():100715. PubMed ID: 32536371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of myelofibrosis after ruxolitinib failure.
    Harrison CN; Schaap N; Mesa RA
    Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Clinical Investigations in Myelofibrosis.
    Venugopal S; Mascarenhas J
    Hematol Oncol Clin North Am; 2021 Apr; 35(2):353-373. PubMed ID: 33641874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety of JAK kinase inhibitors for the treatment of myelofibrosis.
    Coltro G; Vannucchi AM
    Expert Opin Drug Saf; 2021 Feb; 20(2):139-154. PubMed ID: 33327810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
    Bose P; Masarova L; Verstovsek S
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33050168
    [TBL] [Abstract][Full Text] [Related]  

  • 39. JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.
    Bose P; Verstovsek S
    Hemasphere; 2020 Aug; 4(4):e424. PubMed ID: 32903304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.
    Masarova L; Bose P; Pemmaraju N; Daver NG; Zhou L; Pierce S; Sasaki K; Kantarjian HM; Estrov Z; Verstovsek S
    Cancer; 2020 Oct; 126(19):4322-4331. PubMed ID: 32697338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.